Compare Stocks

Compare stocks with our powerful stock comparison tool. Analyze fundamentals, price performance, and key financial indicators to make informed investment decisions. Our tool lets you compare up to ten stocks side by side based on Performance Charts, Price & Volume, MarketRank™, Analyst Ratings, Sales & Book Value, Profitability & Earnings, Dividends, Debt, Ownership, Headlines, and more. Simply enter up to ten stock symbols (e.g., BAC, JPM, WFC, C, GS) to get started and uncover top investment opportunities.

CompanyCurrent Price50-Day Moving Average52-Week RangeMarket CapBetaAvg. VolumeToday's Volume
Larimar Therapeutics, Inc. stock logo
LRMR
Larimar Therapeutics
$3.14
-2.5%
$2.85
$1.91
▼
$6.42
$311.65M0.731.37 million shs1.71 million shs
Sernova Biotherapeutics Inc. stock logo
SEOVF
Sernova Biotherapeutics
$0.07
-2.4%
$0.08
$0.06
▼
$0.14
$26.74M0.935,547 shs829 shs
Tiziana Life Sciences Ltd stock logo
TLSA
Tiziana Life Sciences
$0.62
-8.1%
$0.89
$0.55
▼
$1.90
$73.33M0.49543,357 shs225,244 shs
The Infrastructure's Backbone: 10 Stocks Powering the AI Buildout Cover

The AI boom extends far beyond the biggest tech names. Discover 10 companies supplying the memory, storage, networking, semiconductor manufacturing, and power infrastructure that make AI possible. Learn where the next wave of AI investment opportunities may emerge—and the key risks investors should watch as the global AI buildout accelerates.

Get This Free Report

Compare Price Performance

Company1-Day Performance7-Day Performance30-Day Performance90-Day Performance1-Year Performance
Larimar Therapeutics, Inc. stock logo
LRMR
Larimar Therapeutics
-2.48%+3.97%+29.75%-24.88%-9.51%
Sernova Biotherapeutics Inc. stock logo
SEOVF
Sernova Biotherapeutics
-2.40%-14.25%-24.33%-19.45%-32.57%
Tiziana Life Sciences Ltd stock logo
TLSA
Tiziana Life Sciences
-8.14%+8.90%-38.55%-45.56%-63.28%
CompanyCurrent Price50-Day Moving Average52-Week RangeMarket CapBetaAvg. VolumeToday's Volume
Larimar Therapeutics, Inc. stock logo
LRMR
Larimar Therapeutics
$3.14
-2.5%
$2.85
$1.91
▼
$6.42
$311.65M0.731.37 million shs1.71 million shs
Sernova Biotherapeutics Inc. stock logo
SEOVF
Sernova Biotherapeutics
$0.07
-2.4%
$0.08
$0.06
▼
$0.14
$26.74M0.935,547 shs829 shs
Tiziana Life Sciences Ltd stock logo
TLSA
Tiziana Life Sciences
$0.62
-8.1%
$0.89
$0.55
▼
$1.90
$73.33M0.49543,357 shs225,244 shs
The Infrastructure's Backbone: 10 Stocks Powering the AI Buildout Cover

The AI boom extends far beyond the biggest tech names. Discover 10 companies supplying the memory, storage, networking, semiconductor manufacturing, and power infrastructure that make AI possible. Learn where the next wave of AI investment opportunities may emerge—and the key risks investors should watch as the global AI buildout accelerates.

Get This Free Report

Compare Price Performance

Company1-Day Performance7-Day Performance30-Day Performance90-Day Performance1-Year Performance
Larimar Therapeutics, Inc. stock logo
LRMR
Larimar Therapeutics
-2.48%+3.97%+29.75%-24.88%-9.51%
Sernova Biotherapeutics Inc. stock logo
SEOVF
Sernova Biotherapeutics
-2.40%-14.25%-24.33%-19.45%-32.57%
Tiziana Life Sciences Ltd stock logo
TLSA
Tiziana Life Sciences
-8.14%+8.90%-38.55%-45.56%-63.28%
CompanyConsensus Rating ScoreConsensus RatingConsensus Price Target% Upside from Current Price
Larimar Therapeutics, Inc. stock logo
LRMR
Larimar Therapeutics
3.00
Buy$10.00218.47% Upside
Sernova Biotherapeutics Inc. stock logo
SEOVF
Sernova Biotherapeutics
0.00
N/AN/AN/A
Tiziana Life Sciences Ltd stock logo
TLSA
Tiziana Life Sciences
2.00
HoldN/AN/A

Current Analyst Ratings Breakdown

Latest TLSA, LRMR, and SEOVF Analyst Ratings

DateCompanyBrokerageActionRatingPrice TargetDetails
11/16/2026
Larimar Therapeutics, Inc. stock logo
LRMR
Larimar Therapeutics
Lower Price TargetOutperform$11.00 ➝ $9.00
11/10/2026
Larimar Therapeutics, Inc. stock logo
LRMR
Larimar Therapeutics
Reiterated RatingOutperform
10/19/2026
Tiziana Life Sciences Ltd stock logo
TLSA
Tiziana Life Sciences
UpgradeSell (E+) ➝ Sell (D-)
10/15/2026
Larimar Therapeutics, Inc. stock logo
LRMR
Larimar Therapeutics
Reiterated RatingSell (D-)
9/22/2026
Tiziana Life Sciences Ltd stock logo
TLSA
Tiziana Life Sciences
Reiterated RatingBuy
9/14/2026
Larimar Therapeutics, Inc. stock logo
LRMR
Larimar Therapeutics
Initiated CoverageOutperform$13.00
9/3/2026
Tiziana Life Sciences Ltd stock logo
TLSA
Tiziana Life Sciences
Initiated CoverageBuy
8/26/2026
Tiziana Life Sciences Ltd stock logo
TLSA
Tiziana Life Sciences
Reiterated RatingSell (E+)
(Data available from 11/21/2023 forward. View 10+ years of historical ratings with our analyst ratings screener.)
CompanyAnnual RevenuePrice/SalesCashflowPrice/CashBook ValuePrice/Book
Larimar Therapeutics, Inc. stock logo
LRMR
Larimar Therapeutics
N/AN/AN/AN/A$0.94 per shareN/A
Sernova Biotherapeutics Inc. stock logo
SEOVF
Sernova Biotherapeutics
N/AN/AN/AN/A($0.05) per shareN/A
Tiziana Life Sciences Ltd stock logo
TLSA
Tiziana Life Sciences
N/AN/AN/AN/AN/AN/A
CompanyNet IncomeEPSTrailing P/E RatioForward P/E RatioP/E GrowthNet MarginsReturn on Equity (ROE)Return on Assets (ROA)Next Earnings Date
Larimar Therapeutics, Inc. stock logo
LRMR
Larimar Therapeutics
-$165.67M-$1.63N/AN/AN/AN/A-128.77%-90.08%N/A
Sernova Biotherapeutics Inc. stock logo
SEOVF
Sernova Biotherapeutics
-$11.24M-$0.04N/AN/AN/AN/AN/A-1,111.49%12/17/2026 (Estimated)
Tiziana Life Sciences Ltd stock logo
TLSA
Tiziana Life Sciences
-$18.43MN/AN/AN/AN/AN/AN/AN/AN/A

Latest TLSA, LRMR, and SEOVF Earnings

DateQuarterCompanyConsensus EstimateReported EPSBeat/MissGap EPSRevenue EstimateActual RevenueDetails
12/17/2026N/A
Sernova Biotherapeutics Inc. stock logo
SEOVF
Sernova Biotherapeutics
-$0.0072N/AN/AN/AN/AN/A
11/16/2026Q3 2026
Larimar Therapeutics, Inc. stock logo
LRMR
Larimar Therapeutics
-$0.3514-$0.29+$0.0614-$0.29N/AN/A
9/10/2026Q3 2026
Sernova Biotherapeutics Inc. stock logo
SEOVF
Sernova Biotherapeutics
-$0.0050-$0.01-$0.0050-$0.01N/AN/A
CompanyAnnual PayoutDividend Yield5-Year Annualized Dividend GrowthPayout RatioYears of Consecutive Growth
Larimar Therapeutics, Inc. stock logo
LRMR
Larimar Therapeutics
N/AN/AN/AN/AN/A
Sernova Biotherapeutics Inc. stock logo
SEOVF
Sernova Biotherapeutics
N/AN/AN/AN/AN/A
Tiziana Life Sciences Ltd stock logo
TLSA
Tiziana Life Sciences
N/AN/AN/AN/AN/A
CompanyDebt-to-Equity RatioCurrent RatioQuick Ratio
Larimar Therapeutics, Inc. stock logo
LRMR
Larimar Therapeutics
N/A
4.70
4.70
Sernova Biotherapeutics Inc. stock logo
SEOVF
Sernova Biotherapeutics
N/A
0.03
0.03
Tiziana Life Sciences Ltd stock logo
TLSA
Tiziana Life Sciences
N/AN/AN/A

Institutional Ownership

CompanyInstitutional Ownership
Larimar Therapeutics, Inc. stock logo
LRMR
Larimar Therapeutics
91.92%
Sernova Biotherapeutics Inc. stock logo
SEOVF
Sernova Biotherapeutics
N/A
Tiziana Life Sciences Ltd stock logo
TLSA
Tiziana Life Sciences
N/A

Insider Ownership

CompanyInsider Ownership
Larimar Therapeutics, Inc. stock logo
LRMR
Larimar Therapeutics
4.00%
Sernova Biotherapeutics Inc. stock logo
SEOVF
Sernova Biotherapeutics
N/A
Tiziana Life Sciences Ltd stock logo
TLSA
Tiziana Life Sciences
39.82%
CompanyEmployeesShares OutstandingFree FloatOptionable
Larimar Therapeutics, Inc. stock logo
LRMR
Larimar Therapeutics
71103.88 million100.45 millionOptionable
Sernova Biotherapeutics Inc. stock logo
SEOVF
Sernova Biotherapeutics
8377.64 millionN/ANot Optionable
Tiziana Life Sciences Ltd stock logo
TLSA
Tiziana Life Sciences
10127.26 million76.58 millionOptionable

Recent News About These Companies

BTIG Sticks to Their Buy Rating for Tiziana Life Sciences (TLSA)

New MarketBeat Followers Over Time

Media Sentiment Over Time

Larimar Therapeutics stock logo

Larimar Therapeutics NASDAQ:LRMR

$3.14 -0.08 (-2.48%)
Closing price 11/20/2026 04:00 PM Eastern
Extended Trading
$3.09 -0.05 (-1.46%)
As of 11/20/2026 07:30 PM Eastern
Extended trading is trading that happens on electronic markets outside of regular trading hours. This is a fair market value extended hours price provided by Massive. Learn more.

Larimar Therapeutics, Inc., a clinical-stage biotechnology company, focuses on developing treatments for rare diseases using its novel cell penetrating peptide technology platform. Its lead product candidate is CTI-1601, which is in Phase 2 OLE clinical trial for the treatment of Friedreich's ataxia, a rare, progressive and fatal genetic disease. Larimar Therapeutics, Inc. is based in Bala Cynwyd, Pennsylvania.

Sernova Biotherapeutics stock logo

Sernova Biotherapeutics OTCMKTS:SEOVF

$0.07 0.00 (-2.40%)
As of 11/20/2026 02:39 PM Eastern

Sernova Corp. operates as a clinical-stage regenerative medicine therapeutics company in Canada. The company focuses on the development and commercialization of regenerative medicine therapeutics, including its proprietary Cell Pouch and associated technologies consisting of therapeutic cells and local cellular immune protection. Its Cell Pouch is a novel implantable and scalable medical device which forms a natural environment in the body for the housing and long-term survival and function of therapeutic cells, which release necessary proteins or factors missing from the body to treat chronic diseases as an alternative to daily administration of drugs. Sernova Corp. has a research agreement with the University of Miami to advance the development of Conformal Coating Technology in combination with therapeutic cells within Cell Pouch. Sernova Corp. was incorporated in 1998 and is headquartered in London, Canada.

Tiziana Life Sciences stock logo

Tiziana Life Sciences NASDAQ:TLSA

$0.62 -0.06 (-8.14%)
Closing price 11/20/2026 04:00 PM Eastern
Extended Trading
$0.63 +0.01 (+1.68%)
As of 11/20/2026 07:30 PM Eastern
Extended trading is trading that happens on electronic markets outside of regular trading hours. This is a fair market value extended hours price provided by Massive. Learn more.

Tiziana Life Sciences Ltd, a biotechnology company, focuses on the discovery and development of molecules to treat human diseases in oncology and immunology. The company's lead product candidate in immunology is Foralumab (TZLS-401), a human anti-CD3 monoclonal antibody (mAb) for the treatment of Crohn's, graft versus host, ulcerative colitis, multiple sclerosis, type-1 diabetes, inflammatory bowel, psoriasis, and rheumatoid arthritis diseases. It also develops Milciclib (TZLS-201), a small molecule inhibitor of various cyclin-dependent kinases, tropomycin receptor kinases, and Src family kinases controlling cell growth and malignant progression of cancer; and anti- receptor (IL6R) mAb (TZLS-501), a fully human monoclonal antibody for the treatment of IL6-induced inflammation and to treat COVID-19 patients. Tiziana Life Sciences Ltd was incorporated in 1998 and is headquartered in London, the United Kingdom.Kingdom.